We are thrilled to announce the well-deserved promotion of Christine Landlinger-Schubert to the role of Vice President Preclinical and Translational R&D at OncoOne, effective April 1, 2023!

With nearly 15 years of experience in the biotech industry, Christine has consistently showcased her exceptional skills and dedication. Previously, at AFFiRiS, she led preclinical activities for the development of active immunotherapies. She later joined PhagoMed, now BioNTech Austria, where she played a pivotal role in the development of pharmaceuticals to combat bacterial infections. In 2021, Christine brought her expertise to OncoOne as Director Preclinical and Project Lead Inflammation, taking on significant responsibilities within the company. With her extensive expertise and passion for innovation, Christine is an invaluable asset to our highly motivated, multinational, and dynamic team at OncoOne. We congratulate her on this well-deserved promotion, as her exceptional leadership and profound expertise will undoubtedly play a pivotal role in driving OncoOne’s continued success. Her outstanding contributions will further drive us towards our mission of providing innovative therapies for the treatment of cancer and inflammatory disorders. We are truly fortunate to have Christine as an integral part of our team, and we eagerly anticipate the remarkable accomplishments she will continue to achieve in her elevated role.

Please join us in celebrating Christine’s achievements and wishing her continued success in her new role!